Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

33.3%

2 terminated out of 6 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed with results

Key Signals

3 with results67% success

Data Visualizations

Phase Distribution

4Total
Not Applicable (2)
P 2 (1)
P 4 (1)

Trial Status

Completed4
Terminated2

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05784948Not ApplicableCompleted

Safety and Efficacy of Virtual Reality Mindfulness in Patients With Psychosis

NCT00709202Phase 2Completed

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

NCT01878513Not ApplicableCompleted

Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis

NCT00314327Phase 4Terminated

Optimizing Response in Psychosis Study

NCT01269710Completed

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT00617214Terminated

Schizophrenic Patients Taking Part in Integrated Care Program

Showing all 6 trials

Research Network

Activity Timeline